CTAP101
Total Payments
$548,822
Transactions
14
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $548,822 | 14 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $548,822 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI | OPKO Pharmaceuticals, LLC | $548,822 | 0 |
Top Doctors Receiving Payments for CTAP101
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $548,822 | 14 |
Ad
Manufacturing Companies
- OPKO Pharmaceuticals, LLC $548,822
Product Information
- Type Drug
- Total Payments $548,822
- Total Doctors 0
- Transactions 14
About CTAP101
CTAP101 is a drug associated with $548,822 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is OPKO Pharmaceuticals, LLC.
Payment data is available from 2020 to 2020. In 2020, $548,822 was paid across 14 transactions to 0 doctors.
The most common payment nature for CTAP101 is "Unspecified" ($548,822, 100.0% of total).
CTAP101 is associated with 1 research study, including "Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI" ($548,822).